Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 155 for “"immunotherapies"”.
-
Engineering kinetics of immunotherapies and vaccines
… pave the way to safer and more potent cancer immunotherapies and vaccines via engineered kinetic approaches to administering these compounds.
-
Engineering cytokine immunotherapies via cell surface targeting
… of cytokines as systemically administered immunotherapies has been severely limited by on-target/off-tissue toxicity. One approach to overcome this challenge is to engineer cytokines for intratumoral retention following local administration to isolate their activity to on-target tissue. In …
-
Engineering and characterizing human T cell receptors for cancer immunotherapies
The T cell receptor (TCR) is an heterodimer that binds to a short peptide bound to a product of the major histocompatibility complex (MHC). The chains each contain variable (V) and constant (C) region domains, followed by a transmembrane region. Each V domain contains three loops, called …
-
Design of Antigen-Specific Immunotherapies Through Modulation of Peripheral Tolerance Pathways
… This presents a clear need for antigen-specific immunotherapies (ASITs) capable of selectively modulating autoreactive immune cells while maintaining the patient’s ability to respond to foreign pathogens. Lymphocyte activation is dependent on receiving two signals in tandem: interaction with the …
-
Design of Novel Antigen-Specific Immunotherapies for the Treatment of Autoimmune Disorders
… through the development of antigen-specific immunotherapies (ASIT). In this research, we explore different novel approaches to ASIT focused on chemical conjugation, including the design and development of a new therapeutic class, antigen-drug conjugates (AgDCs). By reversing the paradigm of …
-
Characterizing T Cell Features of Atypical Lymphocytes for the Optimization of Adoptive Immunotherapies
<p>T lymphocytes with atypical antigen targets or mechanisms or antigen recognition have been implemented into therapeutic approaches for the treatment of disease with auspicious results. Two such populations are regulatory T cells (Tregs) and CAR (chimeric antigen receptor-modified) T cells. The …
-
Novel Immunotherapies and Immunoregulation in a Chronic Inflammatory Disease of the Central Nervous System
Multiple sclerosis (MS) is a chronic inflammatory disease of central nervous system (CNS) which is thought to arise from a breakdown of immunological tolerance in CD4 cells. The aim of this thesis is to improve our understanding of regulation mechanisms of T cell-dependent chronic inflammation in …
-
Characterization of anti-tumor T cell specificities to inform engineering of antigen-targeted immunotherapies
… T cells are essential to the success of many immunotherapies, as their receptors can recognize peptide antigens presented by major histocompatibility complexes (MHCs); productive recognition of antigens displayed by tumors results in T cell-mediated killing of the tumor cells. However, it is …
-
Engineering immunity : enhancing T Cell vaccines and combination immunotherapies for the treatment of cancer
… of novel therapeutics and combination immunotherapies to generate a counter-directed network of pro-immunity signals⁴-⁸. In Chapters 2 and 3 of this thesis, we describe methods for enhancing T cell priming against tumor antigens via covalent modification of molecular vaccines to enhance …
-
Developing a co-culture model of ovarian cancer to identify immunotherapies that can overcome TGF-β-induced immunosuppression
… recurrence and subsequent treatment resistance. Immunotherapies have shown limited efficacy against HGSC, which is partly attributed to the presence of immunosuppressive cytokines in the tumor microenvironment (TME), notably transforming growth factor beta (TGF-β). TGF-β suppresses anti-tumor …
-
Defining The Cooperation Between Mhc-I and Mhc-Ii Neoantigen-Driven T Cell Responses to Develop Effective Personalized Immunotherapies
… of improved neoantigen-based personalized immunotherapies.</p>
-
Advancing T Cell–Based Immunotherapies: Identification of Tumor-Specific T Cell Receptor Targets and Mechanisms of Resistance in Solid Tumors
<p>Cancer immunotherapies, such as adoptive cell therapy, have transformed cancer treatment by eliciting durable immune responses. While adoptive cell therapy has demonstrated remarkable success in hematologic malignancies and several solid tumors, most patients with solid tumors either fail to …
-
Developing canine osteosarcoma and human non-small cell lung cancer PDX models to study immunotherapies targeting canine and human T cells
… therapies targeting one's own immune system (immunotherapies) have proven to be effective in extending the quality of life and lifespan for a variety of patients with lung, breast, and prostate cancer. However, patients where their cancer is either unresponsive or become resistant to current …
-
Bayesian Adaptive Clinical Trial Design
… to molecular targeted therapies and immunotherapies, which provide innovative therapeutic modalities for treating cancers. These novel therapeutic agents work through mechanisms that fundamentally differ from standard chemotherapeutic agents, making the conventional trial design …
-
Utilizing the Immunomodulatory Effects of Electroporation for Treating Brain Tumors
… other solid tumors, recent advances in cancer immunotherapies have also shown disappointing outcomes in GBMs. The heterogenous nature of GBMs, the immunosuppressive tumor microenvironment and the restrictive role of blood brain barrier (BBB) are some of the main challenges faced for treating …
-
T cell mediated combination immunotherapy
… Because of this, research into developing new immunotherapies, optimizing existing immunotherapies, and designing new combinations of immunotherapies is still critical in the fight against cancer. Although there have been ongoing successes of individual immunotherapies in the clinic, the …
-
Re-Designing Cancer Immunotherapy to Enhance Anti-Tumor Immunity
… delivery with cGAMP and systemic α-PD-L1 immunotherapies. Using MSC, we delivered various forms of anti-CD3 and/or co-signals to explore their contribution to re-activate T cells inside the TME. Combined α-CD3 and CD40L rather than CD80 leads to superior anti-tumor efficacy compared to …
-
Targeting immunosuppression in the tumor microenvironment and protein-based antagonism of oncogenic K-Ras
… that exclusively drive cancer cell growth, while immunotherapies harness the body's immune system to destroy cancer cells. With these new treatment strategies, tumor regression and complete remission of disease have become attainable for a larger subset of patients. Nevertheless, the fight against …
-
Additive manufacturing of microfluidics for evaluation of immunotherapy efficacy
… network of microchannels for supplying media and immunotherapies to a retained tumor fragment. The device configuration is capable of modelling interactions between tumors and various drug treatments. Tested devices were additively manufactured in Pro3dure GR-10 -a relatively new, high-resolution …
-
Locally Administered Particle-Anchored Cytokines Safely Enhance Cancer Immunotherapy
… against cancer. As one of the most potent cancer immunotherapies, immunostimulatory cytokines have been shown to elicit anti-tumor immune responses in preclinical studies, but their clinical application is limited by severe immune-related adverse events upon systemic administration. None of the …
Page 1 of 8